Background Analysis: US FDA Advisory Committee to Review Ardea’s Lesinurad for Gout – OCT 23, 2015 (AAC)

The US FDA has scheduled an Arthritis Advisory Committee (AAC) meeting for Friday, October 23, 2015 to discuss new drug application (NDA) 207988 for lesinurad oral tablets, submitted by Ardea Biosciences, Inc. (Ardea), for the treatment of hyperuricemia associated with gout, in combination with a xanthine oxidase inhibitor. As of June 2012, Ardea has been a wholly-owned subsidiary of AstraZeneca, Inc. (AstraZeneca).

See the SAC Tracker report